Continuous IV monitoring system developer ivWatch announced that it received FDA clearance for its new SmartTouch disposable sensor. SmartTouch is indicated for the early detection of peripheral IV infiltration and extravasation events. The latest FDA clearance expands ivWatch’s sensor portfolio to include the single-use sensor for all patient age groups. It is miniaturized and disposable and […]
ivwatch
ivWatch pulls in $1.5m
Continuous IV monitoring system developer ivWatch filed an SEC Form D to confirm the sale of $1.5 million in an equity offering. Newport News, Va.-based ivWatch is offering a total of $13 million in equity, leaving $11.5 million remaining to be sold, according to the SEC filing. The company did not disclose the issuer size […]
ivWatch announces new executives
ivWatch announced that it made three additions to its executive management team, appointing Teresa “Terry” Blevins, Erin Wendell and Paul Stoddard to executive roles. Blevins is tabbed as the Newport News, Va.–based company’s new CFO, while Wendell is set to become chief marketing officer and Stoddard is the new VP of sales. They will all […]
ivWatch inks distro deal for IV monitoring device
ivWatch said this week that it landed an international partner to manage the distribution of its continuous intravenous monitoring device. The Hampton, Va.-based company inked a deal with supplier New Medical to distribute its ivWatch Model 400 system in Australia and New Zealand. Get the full story at our sister site, Drug Delivery Business News.
ivWatch inks development, commercialization deal with ICU Medical
ivWatch said today that it inked a long-term development and commercialization deal to integrate its continuous IV monitor into new medical devices and systems made by ICU Medical (NSDQ:ICUI). The deal paves the way for EHR interoperability, according to ivWatch, by connecting the two companies’ systems and enabling the exchange of data. Get the full story at our […]
ivWatch wins CE Mark for continuous IV site monitor
ivWatch said today that it won CE Mark clearance for its intravenous infiltration/extravasation monitoring device. The company’s ivWatch Model 400, which has FDA clearance, is sold in the U.S. through group purchasing contracts with Premier and Vizient. Get the full story at our sister site, Drug Delivery Business News.
7 medtech stories we missed this week: August 3, 2018
From Esaote launching its new ultrasound device to Nipro’s Infraredx launching in Japan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Esaote launches new ultrasound devices Esaote announced in an Aug. 2 press release that it has launched its new MyLab X7, MyLab X6 and MyLab X5 ultrasound […]
ivWatch wins medical device license in Canada
ivWatch said today that it landed a medical device license from Health Canada permitting the sale of its intravenous infiltration/extravasation monitoring device. The company’s FDA-approved sensor, which is roughly the size of a pencil eraser, uses light to measure the optical density of the tissue surrounding an IV insertion site, monitoring the flow of fluid as […]
ivWatch to integrate IV infiltration sensor into Philips’ patient monitors
For decades, nurses have sent drugs surging through a patient’s body using the power of the circulatory system. Catheters deliver medications destined to travel through a person’s veins – but it doesn’t always turn out that way. Sometimes, leaky veins cause drugs to seep into surrounding tissue or to back out of the insertion site, […]
7 medtech stories we missed this week: Sept. 29, 2017
From EOI getting FDA clearance to Sanuwave’s new joint venture agreement, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. EOI wins FDA nod for FLXfit15 expandable cage EOI announced in a Sept. 28 press release that it has received FDA 510(k) clearance for its FLXfit 15. The clearance […]
ivWatch raises $14.8m for infusion therapy tech
ivWatch said today that it closed a $14.8 million financing round to support the company’s direct go-to-market initiatives and strategic partners activities. Undisclosed angel investors, family funds and a major hospital system invested in the round, according to the company. Get the full story at our sister site, Drug Delivery Business News.
